HER2 Breast Cancer

Latest News

Oncology pharmacist, Breast Cancer, Oncology, Treatment | Image Credit: Dragana Gordic | stock.adobe.com
Advancing Precision Oncology: The Role of Targeted Therapies in HR+, HER2– Breast Cancer

January 22nd 2025

A panel of experts discuss treatment of HR+, HER2– breast cancer with therapies such as ribociclib, alpelisib, everolimus, and elacestrant.

Bispecific antibodies | Image Credit: © Александр Михайлюк - stock.adobe.com
KN026 and Docetaxel Show Promise as First-Line Treatment for HER2+ Metastatic Breast Cancer

January 21st 2025

Microscopic view of metastatic breast cancer cells development and progression | Image Credit: © ratirath - stock.adobe.com
Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2– Metastatic Breast Cancer

January 18th 2025

FDA approval seal -- Image credit: Aquir | stock.adobe.com
FDA Approves Dato-DXd for Adults With Unresectable or Metastatic HR+, HER2- Breast Cancer

January 17th 2025

Breast cancer cells | Image Credit: © Jack - stock.adobe.com
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer

January 15th 2025

More News

FDA OKs Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation

FDA OKs Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation

Jennifer Barrett, Associate Editor
October 16th 2018

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Read More

Sequential Regimen for HER2+ Breast Cancer Non-Inferior to Concurrent Treatment

Sequential Regimen for HER2+ Breast Cancer Non-Inferior to Concurrent Treatment

Jennifer Barrett, Associate Editor
September 19th 2018

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Read More

<12345